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a b s t r a c t
Multiple sclerosis is a chronic demyelinating disease of the central nervous system that
occurs primarily in young adults. There is no single diagnostic test to recognize the disease.
The diagnostic criteria, based on clinical examination and laboratory tests, have changed
considerably over time. The ﬁrst guidelines involved only the results of the patient's
neurological examination. The diagnostic criteria developed by Poser in 1983 were based
largely on the results of additional tests, including visual evoked potentials and analysis of
cerebrospinal ﬂuid. The McDonald criteria, developed in 2001and updated in 2005 and 2010,
reﬂected the diagnostic breakthrough caused by widespread use of magnetic resonance
imaging (MRI). Currently, the diagnosis depends largely on the results of the MRI examina-
tion. An early diagnosis is particularly important for starting disease-modifying treatments.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Multiple sclerosis (MS) is a chronic autoimmune demyelinat-
ing disease of the central nervous system (CNS), and the
aetiology is still not fully understood. There is currently no
single diagnostic test for MS. The most common tool used to
support the clinic-based diagnosis is magnetic resonance
imaging (MRI). Over the last ten years the criteria for
diagnosing MS have changed considerably, as have the
improvements of MRI. Examination of the cerebrospinal ﬂuid
(CSF), to demonstrate an increase of immunoglobulin produc-
tion, was formerly considered one of the basic diagnostic tests,* Corresponding author at: 2nd Department of Neurology, Institute of Ps
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Sbut it lost its importance in the MRI era. Still, the diagnostic
methods have many limitations and are often not speciﬁc
enough for a diagnosis of MS, especially in the early stages of
the disease. As early initiation of disease-modifying therapy is
important, the diagnostic process is both a medical and ethical
challenge.
2. The ﬁrst guidelines for recognizing MS
The ﬁrst physician who described the clinical features typical
for MS was Jean-Martin Charcot (reviewed by [1]). Nystagmus,
intention tremor, and scanning speech were the triad ofychiatry and Neurology, ul. Sobieskiego 9, 02-957 Warsaw, Poland.
@wum.edu.pl (D. Mirowska-Guzel), czlonkow@ipin.edu.pl
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was said to be characteristic of MS. It turned out, however, that
this group of symptoms typically occurred in advanced stages
of the disease, and also appeared in a number of neurological
disorders, particularly those associated with damage to the
cerebellum [2,3].
In 1906, Marburg also attempted to develop criteria for the
diagnosis of MS. He stated that the co-occurrence of Uhthoff's
phenomenon (worsening of neurological symptoms when the
body's temperature increases), pyramidal signs, and a lack of
plantar reﬂex was enough to make a diagnosis. Both Charcot's
triad and the criteria of Marburg had low speciﬁcity (reviewed
by [4]).
In 1954, ﬁrst clinical classiﬁcation of MS made by Allison
and Milliar appeared (reviewed by [1]). This classiﬁcation
recognized the appearance of clinical symptoms at different
time points in different regions of the central nervous system
(CNS) as typical for MS. Until then, the terms ‘‘dissemination in
time (DIT)’’ and ‘‘dissemination in space (DIS)’’ were used to
describe the characteristics of MS [5]. The authors of this ﬁrst
contemporary deﬁnition divided the patients into the follow-
ing groups ‘‘early’’, ‘‘possible’’ and ‘‘probable’’ MS. That was
the ﬁrst time the patients' reports of symptoms were taken
into account. The division of patients into the groups,
mentioned above, was later used by Schumacher, who
developed the ﬁrst modern diagnostic criteria for MS [6].
According to Schumacher, 1965, all the following conditions
had to be met to diagnose clinically deﬁnite MS:
a) the presence of objective symptoms during the neurological
examination;
b) at least two symptoms suggesting the involvement of
different regions of CNS present in the neurological
examination or documented in the medical history;
c) the presence of symptoms resulting mainly from white
matter lesions;
d) at least two documented relapses, with symptoms lasting a
minimum of 24 h, and at least 1 month between the
relapses or the progression of symptoms within 6 months
of observation;
e) patient aged between 10 and 50 years;
f) other diseases causing similar symptoms were less probable.
Over the next few years, it was repeatedly pointed out that
Schumacher's criteria were too restrictive. There were
attempts to improve them (e.g. by McAlpine, Lumsden,
Acheson) [4], but without much success. The only accepted
change was removing the age limit from the criteria in the
modiﬁcation by Rose, published in 1976 [7].
3. Poser criteria
Poser et al. created new diagnostic criteria for MS in 1983 for
clinical trials [8]. These were based on Schumacher's previous
criteria. Five possible diagnoses were identiﬁed:
1) clinically deﬁnite MS;
2) clinically probable MS;
3) laboratory supported deﬁnite MS;4) laboratory supported probable MS;
5) not MS [8].
Poser et al. suggested screening only patients that met the
criteria of deﬁnite and probable MS [8].
The main clinical feature of MS was a ‘‘relapse’’, also called
‘‘the neurological worsening.’’ The deﬁnition of a relapse was
an acute or subacute onset of neurological symptoms ‘‘typical
for MS’’ which had to be present for at least 24 h and weren't
due to an infection. These symptoms had to be observed
during the patient's examination, or if they existed in the past,
were reported accurately by the patient. Calling the symptoms
‘‘typical for MS’’ Poser discarded such unspeciﬁc symptoms as
headaches, disturbances of consciousness or psychiatric
symptoms. Also, the authors recommended caution when
classifying relapse symptoms described only by the patient,
and not documented by a clinical examination [8].
Poser criteria allowed a diagnosis of clinically deﬁnite MS
to be made if there were at least two relapses (DIT) and if there
was clinical evidence of damage to at least two structures
of the CNS (DIS). The second neurological worsening was
recognized as a second relapse if at least 30 days had passed
since the start of the recovery from a previous exacerbation of
the disease.
Laboratory supported deﬁnite MS could be diagnosed when
there was clinical evidence of damage to one region of the CNS,
but abnormalities in laboratory tests pointed to additional
subclinical damage in a different placement.
A new part of the diagnostic criteria considered the
laboratory tests (evoked potentials, CSF examination, and MRI
scan), which had only a supporting role in the diagnostic
process, – e.g. abnormalities in these studies equalled the
clinical evidence of structural damage to the CNS. It was
necessary to identify at least one clinical relapse to diagnose MS.
Of the above-mentioned laboratory tests, a special role was
attributed to the CSF study (which conﬁrmed the intrathecal
synthesis of immunoglobulin). Widely used since the 1950s
globulin tests and the colloidal gold test [9] were gradually
replaced by the calculation of the IgG index and the presence of
oligoclonal bands in the CSF that demonstrated intrathecal IgG
synthesis. An elevated IgG index or the presence of oligoclonal
bands in the CSF was used to diagnose laboratory supported
MS [10].
Another group of laboratory tests useful in supporting the
diagnosis were the electrophysiological examinations. Speciﬁc
abnormalities found in evoked potentials were equivalent to
the silent lesions of the CNS. Prolonged latencies of visual
evoked potentials (VEP) indicated damage to the optic nerve or
visual pathways, brainstem auditory evoked potentials (BAEP)
indicated a lesion of the brainstem, and somatosensory
evoked potentials (SSEP) indicated damage to the sensory
pathways at the level of the spinal cord and brainstem.
At that time, there were no standard procedures for
assessing MS lesions by MRI, nevertheless, showing lesions
by MRI could support the diagnosis. Also, the availability of
MRI in clinics was still very limited [11,12].
The authors advocated caution when diagnosing MS in
patients with only one conﬁrmed clinical relapse and
abnormalities in the laboratory tests [8]. In this situation
there was a risk of misdiagnosing a patient who could suffer
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diseases, such as Borrelia burgdorferi infection or CNS syphilis,
autoimmune diseases, such as acute disseminated encepha-
lomyelitis (ADEM), or degenerative disorders, such as vitamin
B12 deﬁciency or Friedreich's ataxia. Therefore, special care
was advised when diagnosing MS when both types of changes
(clinical and laboratory) appeared at the same time [8,11].
4. McDonald criteria
The development of radiological scans, particularly MRI, as
well as the introduction of the ﬁrst disease-modifying drug-
interferon beta, into the European market in 1996 called for the
further changes in the MS diagnostic criteria. The researchers
aimed for a quicker and more accurate diagnosis of MS in its
early stage, when the potential treatment effect was thought
to be the largest [13].
In 2001, the International Panel on MS Diagnosis chaired by
Ian McDonald developed new criteria for diagnosing MS, now
known as the ‘‘McDonald criteria’’ [14].
Several important changes were introduced to the Poser
criteria. The classiﬁcations of clinically or laboratory sup-
ported deﬁnite or probable MS were abandoned because such
divisions did not correlate with the further clinical course [14].
The number of diagnoses was reduced to three: ‘‘MS’’,
‘‘possible MS’’ and ‘‘not MS’’. The diagnosis of MS was given
when the disease had a typical clinical course and met all the
required criteria. Possible MS referred to a situation when the
symptoms presented by the patient indicated MS, but did not
meet the McDonald criteria; therefore further observation of
the patient was required [15,16]. The ‘‘not MS’’ diagnosis
excluded the disease [14].
McDonald et al. also modiﬁed the deﬁnition of relapse,
stressing that the symptoms must have a duration of at least
24 h and may not be associated with fever or other symptoms
of infection. The necessity of a 30-day gap between the two
relapses remained, so they would be considered separately.Table 1 – Radiological criteria of 'dissemination in space' (DIS):
Original McDonald criteria (2000) Modiﬁed McDonal
(ﬁrst revision, 
Three conditions out of four must be met:
1. At least one gadolinium-enhancing
lesion must be present or at least 9
T2 hiperintensive lesions must be
present if gadolinium-enhancing
lesions are absent.
2. At least one infratentorial lesion
must be present.
3. At least 1 subcortical lesion must
be present.
4. At least 3 periventricular lesions
must be present.
Three conditions out of fo
1. At least one gadoliniu
lesion must be presen
T2 hiperintensive lesi
present if gadolinium
lesions are absent.
2. At least one infratent
must be present.
3. At least 1 subcortical 
be present.
4. At least 3 periventricu
must be present.
Important: The lesion in the spinal cord is equivalent to the infratento
equivalent to the gadolinium-enhancing lesion in the brain. The lesions
meet the required number of 9 lesions.
a Gadolinium-enhancing lesions are not required for DIS.
b If the patient has a relapse with spinal or truncal symptoms, the lesionThey also modiﬁed the deﬁnition of such a gap. It was accepted
that 30 days had to pass between the onset of neurological
symptoms suggestive of a relapse and the appearance of the
next neurological worsening (not since the ‘‘early recovery’’,
recommended by Poser). It was also stated that the paroxys-
mal movements may be treated as a relapse only if they
appeared several times within at least 24 h [14].
Another change was an increase in the importance of CNS
imaging using MRI techniques in the process of diagnosing MS.
In the Poser criteria, MRI played only a supporting role and was
used mainly as a tool for ﬁnding a second, subclinical
outbreak; while it became as important as a clinical evaluation,
and was mandatory if DIT or DIS could not be documented by
neurological examination.
Radiological DIS could be proven if there were sufﬁcient
numbers of lesions suggestive of demyelination (with clear
edges, greater than 3 mm in diameter) and these lesions met
the radiological criteria for MS (developed by Barkhoff,
modiﬁed by Tintore) (Table 1) [11,17–19]. According to MRI
criteria at al. these MRI criteria signiﬁcantly raised the
speciﬁcity of the diagnosis, while not greatly changing the
sensitivity; thus, they were incorporated into the McDonald
criteria.
The DIS was also proven when the MRI indicated the
existence of lesions suggestive of demyelination, but their
number and localization made them insufﬁcient to satisfy the
criteria. If such a situation occurred, the presence of two
lesions typical of MS in MRI in conjunction with the presence
of oligoclonal bands or an elevated IgG index in the CSF were
considered sufﬁcient to prove DIS.
The new criteria also introduced the possibility of radio-
logical DIT. To prove DIT, the co-existence of new and old
lesions had to be demonstrated by MRI (Table 2).
The relapsing-remitting form of MS (RRMS) could still be
diagnosed only after the second relapse, but patients could
meet the McDonald criteria for MS before the second relapse
happened. This group is deﬁned in the medical literature as
'McDonald MS' and includes patients: a comparison.
d criteria
2005)
Modiﬁed McDonald criteria
(second revision, 2010)
ur must be met:
m-enhancing
t or at least 9
ons must be
-enhancing
orial lesion
lesion must
lar lesions
'Dissemination in space' may be demonstrated
by a presence of at least 1 T2 hiperintensive
lesiona in 2 out of 4 typical locations:
 periventricular
 subcortical
 infratentorial
 in the spinal cordb.
rial lesion. The gadolinium-enhancing lesion in the spinal cord is
 in the spinal cord can be counted together with the brain lesions to
 responsible for these symptoms should not be counted.
Table 2 – Radiological criteria of 'dissemination in time' (DIT): a comparison.
Original McDonald criteria (2000) Modiﬁed McDonald criteria
(ﬁrst revision, 2005)
Modiﬁed McDonald criteria
(second revision, 2010)
DIT can be proven by: DIT can be proven in two ways: DIT can be proven in two ways:
a) By a presence of at last one gadolinium-enhancing
lesion in the brain in the MRI scan performed at least
3 months after the onset of ﬁrst clinical symptoms*.
This lesion should not be the one responsible for
the clinical symptoms.
a) By a presence of gadolinium-enhancing
lesion in a MRI scan performed at least
3 months after the onset of ﬁrst clinical
symptoms. This lesion should not be
the one responsible for the clinical symptoms.
a) By a presence of a new
T2 hiperintensive lesion or a
gadolinium-enhancing lesion
in the next MRI scan. The time
of the previous MRI scan is
not important.
b) By a presence of a new T2 hiperintensive lesion
or a gadolinium-enhancing lesion in the second
MRI scan performed not sooner than 3 months
after the ﬁrst.
b) By a presence of a new T2 hiperintensive
lesion in the next MRI scan if the previous
one was done at least 30 days after the
onset of ﬁrst clinical symptoms.
b) By a presence of both
gadolinium-enhancing and
non-enhancing lesions in the
ﬁrst MRI scan. The time of
the MRI scan is not important.
* If the first MRI scan is done too early, it cannot be used for diagnosing DIT. Performing a second MRI scan no sooner than 3 months after the
onset of clinical symptoms is recommended.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 1 3 – 3 2 1316- after the ﬁrst multifocal relapse,
- after two relapses with a single neurological symptom and
those
- with clinically isolated syndrome (CIS) [11,20,21].
With the increasing importance of MRI of the brain, the role
of other laboratory tests diminished. An MRI of the spinal cord
was not included in the criteria, despite all the evidence
suggesting lesions typical for MS may exist there, due to a lack of
data from clinical trials. To satisfy the criteria, CSF examination
was indicated only when MRI alone could not prove the DIS.
McDonald at al. recommended VEP only if subclinical damage to
the optic nerve was suspected. Other evoked potentials (SSEP,Table 3 – McDonald diagnostic criteria for Multiple Sclerosis: a
Clinical symptoms: Additional conditions 
be met to make diagn
(the original McDonald c
2005 revision of the McDo
Two or more relapses and at least
two different clinical symptoms.
Not needed 
Two or more relapses and only
one clinical symptom.
Dissemination in space proven by
or
Wait for the relapse with differen
One relapse and at least two
different clinical symptoms.
Dissemination in time proven by
or
Two or more T2 hiperintensive le
scan together with presence of ol
or elevated IgG index in cerebros
or
Wait for the second relapse.
One relapse and only one clinical
symptom (clinically isolated
syndrome).
Dissemination in time proven by
or
Two or more T2 hiperintensive le
together with presence of oligoclo
elevated IgG index in cerebrospin
and
Dissemination in space proven by
Alternatively
Wait for the second relapse with 
symptomatology.BAEP) were not included in the criteria because they did not
contribute relevant data for the diagnosis of MS [20].
To summarize, MS according to the original McDonald
criteria could be identiﬁed solely on the basis of clinical
evaluation or with the help of additional laboratory tests
(Table 3). It should be noted that McDonald at al. did not allow
the symptoms reported by the patient to be counted as a relapse.
In each case the lack of clinical proof for DIT or DIS indicated the
need to perform an MRI scan of the brain. For the patients with
CIS it was necessary to prove both DIS and DIT by MRI.
The original criteria were characterized by a good predictive
value. In two large clinical trials evaluating the usefulness of
McDonald criteria, Dalton et al. found that both the sensitivity comparison.
that must
osis of MS
riteria and a
nald criteria):
Additional conditions that must
be met to make diagnosis of MS
(a 2010 revision of McDonald criteria):
Not needed
 MRI scan
t symptomatology.
Dissemination in space proven by MRI scan
or
Wait for the relapse with different
symptomatology.
 MRI scan
sions in MRI
igoclonal bands
pinal ﬂuid
Dissemination in time proven by MRI scan
or
Wait for the second relapse.
 MRI scan
sions in MRI scan
nal bands or
al ﬂuid
 MRI scan
different
Dissemination in time proven by MRI scan
or
Wait for the second relapse
and
Dissemination in space proven by MRI scan
or
Wait for the second relapse with different
symptomatology.
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Tintore et al. deﬁned the sensitivity of the criteria at 74% and
speciﬁcity at 86% [12,22].
4.1. Modiﬁcations to the McDonald criteria in 2005 and
2010
Since the year 2000, the experts of the Panel on MS Diagnosis
(further referred to as the Panel) gathered twice (2005, 2010) to
develop modiﬁcations to the McDonald criteria [16,17]. The
modiﬁcations were meant to facilitate and speed up the
diagnostic process.
In the introduction the Panel stressed that the McDonald
criteria should serve as an aid, not as a basis in the diagnostic
process. McDonald criteria have been developed for a group of
patients whose clinical symptoms are characteristic of the
demyelinating process. It should be noted that they were
tested for a Western adult population and do not apply to
children and people from other ethnic groups [17]. The clinical
features typical for the demyelinating process were symptoms
lasting over 24 h suggesting structural damage of the brain
hemispheres, brainstem, cerebellum or partial lateral damage
of the spinal cord [16]. Patients with non-characteristic
symptoms, both because of their nature (such as cognitive
dysfunction, encephalopathy or seizures) or clinical course
(one-phase) should not be assessed by McDonald criteria. In
such patients a search for other diseases should be performed.
Lesions on MRI that appear similar to MS lesions can occur in a
number of other diseases, including:
- Acute disseminated encephalomyelitis (ADEM),
- Transverse myelitis,
- Devic's disease,
- Sarcoidosis of CNS,
- Behcet's disease,
- CNS vasculitis,
- Systemic Lupus Erythematous,
- CNS lymphoma [16,21].
The examples of differential diagnosis, divided into
radiological and clinical groups, can be found in Table 4. A
full list of 'red ﬂags' that were atypical for MS features and
should prompt the search for a different diagnosis was created
in 2008 by Miller et al. [20].Table 4 – Differential diagnosis of MS.
Differential diagnosis group Diseases
Radiological - Tumour (glioma, isolated CNS
lymphoma, tumefactive MS)
- neuromyelitis optica
- ADEM
- Balo's concentric sclerosis
Clinical - neuroboreliosis
- myelopathy
- vasculitis
- sarcoidosis
- syphilis
- neurocysticercosis
- Behcet's diseaseThe modiﬁcation in 2005 reduced the time needed to prove a
radiological DIT (Table 2). The clinician could adopt a strategy of
a 3-month wait after the ﬁrst relapse. If an MRI, performed after
that time, showed even one lesion enhanced after administer-
ing gadolinium to the patient, it was enough to satisfy the
radiological criteria for DIT. An MRI scan performed before that
time (between 30 days and 3 months after the onset of clinical
symptoms) was treated as a reference test. An occurrence of any
new lesion in the next MRI scan proved the DIT.
The Panel pointed out that the new lesion should be large
enough to ascertain that it was not omitted in the previous MRI
scan due to technical reasons [17,19].
The Panel included MRI of the spinal cord in the 2005
modiﬁed criteria (Table 1). A lesion in the spinal cord was the
equivalent of an infratentorial lesion, according to the Barkh-
off and Tintore criteria. It could be also counted together with
the lesions of the brain to meet the required number of lesions.
The Panel determined that an MRI of the spinal cord could also
be used to meet the radiological criteria for DIT. For that, the
presence of at least one gadolinium-enhancing lesion was
required. However, it was not recommended to routinely scan
the spinal cord. Such an MRI was justiﬁed only if there were
new symptoms suggesting damage of the spinal cord [12].
In 2010, the McDonald criteria were modiﬁed for the second
time.
The Panel based on the study results demonstrated by the
MAGNIMS (European Magnetic Imaging in MS) group, changed
the criteria for radiological DIS (Table 1). The new criteria
stated at least one lesion typical for MS lesion in at least two
out of four locations typical for MS should be present in the
MRI. The typical locations are: periventricular, subcortical,
infratentorial, and in the spinal cord. It was emphasized that at
the time of the MRI scan, the patient has clinical symptoms
indicating the involvement of one of the CNS lesions, this
lesion should not be counted [19].
In 2010, the Panel also rejected the radiological criteria of
Barkhoff and Tintore. The modiﬁcations were dictated by the
higher sensitivity of the new criteria in making the diagnosis,
while the speciﬁcity remained unchanged [13,16,19].
The Panel also recognized that MRI scans to prove the DIT
may be performed earlier than recommended in the previous
criteria (which was a minimum of 30 days after the onset of
clinical symptoms). The coexistence of gadolinium-enhancing
and non-enhancing lesions was considered sufﬁcient to prove
DIT (Table 2). The lack of a reference MRI did not change the
speciﬁcity in diagnosing MS. In the most recent McDonald
criteria, DIT can be proven on the basis of the result of the ﬁrst
MRI without specifying a time frame in which the scan should
be performed. This applies to both the MRI of the brain and the
spinal cord [19].
Due to the change in the criteria of DIS, once again the role
of CSF testing was diminished. The earlier McDonald criteria
made it possible to bypass the Barkhoff radiological criteria if
the results of CSF tests were positive (elevated IgG index,
presence of oligoclonal bands) [18,19]. With the modiﬁcation
proposed by the MAGNIMS group, CSF testing was removed
from the McDonald criteria for RRMS. This does not mean that
it should not be performed. It continues to play an important
role in the differential diagnosis of MS and in diagnosing the
primary progressive form of MS [21].
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relapse-typical symptoms reported by the patient only.
However, it was stressed that the diagnosis of MS requires
conﬁrmation by clinical examination or by additional tests
after at least one clinical relapse.
To summarize, the newest criteria make it possible to
identify MS 3 months earlier than allowed by the original
McDonald criteria and 1 month earlier than the 2005 criteria,
provided that DIT and DIS are proven by MRI (Table 3). It is not
necessary to repeat the brain MRI if the ﬁrst one meets the
criteria. The number of MRI scans performed depends on the
clinical situation. The new criteria also allow the start of
disease-modifying therapy when the ﬁrst clinical symptoms of
MS appear.
4.2. Subtypes of MS
Originally, in 1996, the course of MS was categorized into four
main subtypes: relapsing-remitting, primary progressive,
secondary progressive, and progressive relapsing MS [23].
According to the 2014 revision, the newly described
subtypes were:
1) clinically isolated syndrome (CIS),
2) relapsing-remitting MS (RRMS),
3) secondary progressive MS (SSMS),
4) primary progressive MS (PPMS) [24].
Clinically isolated syndrome is the ﬁrst clinical manifesta-
tion of the disease. In CIS there is no evidence of previous
episodes of demyelination, not even from the patient's
medical history [24].
The vast majority of patients suffering from MS have the
relapsing-remitting subtype [23,24].
During the course of RRMS, we observe clearly deﬁned
relapses with full recovery (or residual deﬁcit upon recovery).
There is no disease progression during the periods between
relapses. The SPMS is characterized by an initial RRMS course
followed by gradual worsening with or without relapses. The
diagnosis of SPMS is made retrospectively [25,26]. The PPMS
could be described as a progressive accumulation of disability
from the disease onset with occasional plateaus, temporary
minor improvements, or acute relapses still consistent with
the deﬁnition [27].
4.3. Clinically isolated syndrome
The ﬁrst clinical sign of MS with no radiological evidence (can
be a single or multiple lesions, possibly of demyelinating
origin, but no DIT) could be classiﬁed as CIS [28]. A symptom
that is classiﬁed as CIS should last for at least 24 h so it is
isolated in time but not necessarily in space [29]. Most often a
patient with CIS presents with one of the following:
a) sensory symptoms such as: numbness, coldness, tightness,
tingling, pins-and-needles, swelling of the limb or trunk;
b) ophthalmological manifestations: most commonly optic
neuritis (presented as unilateral eye pain that is aggravated
by ocular movements and variable decreases of visual
acuity decrease);c) motor symptoms: weakness of arms, legs, spasticity,
pathological reﬂexes;
d) diplopia (result of lesions in the brainstem or cerebellar
pathways);
e) coordination problems such as gait imbalance, slurred
speech, dysmetria, intention tremor (cerebellar or cere-
bello-vestibular connection dysfunction);
f) vertigo [30].
A distinct portion of patients presenting with CIS convert to
MS within 10 years [28]. There is discussion among neurol-
ogists on how to treat CIS, because a lot of evidence suggests
that an early start of disease-modifying therapies for CIS
patients may delay the conversion to MS [31].
4.4. Radiologically isolated syndrome
In the era of the new developments in MRI techniques, more and
more often T2 hyperintense lesions could be found in locations
typical for MS in the brains of patients with a history suggestive
of MS. The most frequent reasons for performing MRI are:
migraine and other headaches, depression, head injury, loss of
consciousness and tinnitus [32–34]. In such cases, caution
should be exercised. Informing the patient of the suspected MS
in the absence of clinical proof can lead to stigmatization of the
patient and huge psychological strain [35]. It is worth noting that
radiologist often described lesions in the brain as 'hyperintense
lesions in the white matter that might be inﬂammatory,
vascular or demyelinating', which demonstrates the difﬁculties
in characterizing such lesions during routine scans [36].
Nevertheless, such a radiological description may cause a great
deal of anxiety to the patient [37].
The newly described RIS is a clinical condition in which
there may be suspicion of a demyelinating process, but the
lack of typical clinical features prevents the physician from
diagnosing MS. The RIS can be identiﬁed only when the
radiological criteria of Barkhoff and Tintore are met in the
absence of clinical relapses or neurological symptoms char-
acteristic of MS [38]. Changes seen in MRI can be observed as
DIS and DIT. The DIS can be demonstrated by a minimum of
one T2 lesion (not necessarily gadolinium-enhanced) in at
least four areas of the CNS:
1) periventricular,
2) juxtacortical,
3) infratentorial,
4) spinal cord (if a subject has a brainstem or spinal cord
syndrome, the symptomatic lesions are excluded from the
criteria and do not contribute to the lesion count).
The DIT can be demonstrated by:
1) a new T2 and/or gadolinium-enhancing lesion(s) on follow-
up MRI, with reference to a baseline scan, irrespective of the
timing of the baseline MRI;
2) simultaneous presence of asymptomatic gadolinium-en-
hancing and nonenhancing lesions at any time.
In a large randomized clinical trials, around 30% of subjects
with RIS developed CIS within 2 years [16,33,39].
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RIS. Sellner et al. proposed to adopt a strategy of 'waiting' or a
strategy of 'follow-up' [38]. The ﬁrst strategy of 'waiting' was
reduced to wait for the ﬁrst clinical relapse; while, the strategy
of 'follow-up' was to repeat imaging studies: after 6 months,
then after 24 months, to follow the possible progression of MR
changes [39,40].
Distinguishing between demyelinating and natural age-
related radiological MRI changes can be one of the most
difﬁcult diagnostic issues [41]. The majority of studies
evaluating age-related changes were conﬁrmed on post-
mortem examination [42]; thus it is extremely demanding to
discriminate these two types of changes on MRI scans. Typical
age-related MRI changes are:
1) enlarged perivascular (Virchow-Robin) spaces,
2) reduction in white-matter volume,
3) enlarges perivascular spaces,
4) small vessel ischaemia,
5) degeneration of myelin and axons [42,43].
5. Diagnostic criteria for children with MS
From the ﬁrst cases of MS diagnosed in children neurologist
have had particular problems distinguishing MS from other
disorders. Due to high similarity between the ﬁrst MS clinical
manifestation and ADEM in childhood, it is a diagnostic
challenge for clinicians to diagnose MS accurately after the
ﬁrst relapse [44]. The McDonald diagnostic criteria are
adequate for children older than 12 years but are not speciﬁc
and sensitive enough for those younger [45,46].
Nowadays to diagnose a child with MS we need to ﬁnd at
least one of the following features:
a) two or more nonencephalopatic (especially not ADEM)
clinical central nervous system events connected with
more than one area of the CNS, with possible inﬂammatory
origin, separated by more than 30 days;
b) one nonencephalopathic MS typical episode associated
with MRI ﬁndings (consistent with 2010 McDonald criteria
for DIS), in which a follow-up MRI shows at least one new
enhancing or nonenhancing lesion consistent with the
criteria for DIT;
c) one ADEM attack followed by a nonencephalopathic clinical
event, 3 or more months after symptom onset, that is
associated with new MRI lesions fulﬁlling the 2010
McDonald DIS criteria;
d) a ﬁrst, single, acute event that does not meet ADEM criteria,
and MRI ﬁndings that are consistent with the 2010
McDonald criteria for DIS and DIT (applies to children ≥12
years old) [47].
6. MS diagnosis in different ethnic groups
Although there is one set of diagnostic criteria for MS in
adults of any origin, there are some differences in clinicalcharacteristics between ethnic groups. The majority of studies
that contributed to the MS criteria included Caucasian subjects
[48]. However, there is some distinctiveness among Asians,
Africans and Hispanics. First, MS is recognized less frequently
in each of these groups compared with Caucasians [48–50].
People in Asia present with optic nerve and spinal cord
disturbances more often than Caucasian population [49]. A
recent publication demonstrated that the incidence of
neuromyelitis optica (NMO) among Asians may be higher
than previously though [50]. Africans are theoretically have
the same risk as Caucasians, but only for males [48]. Several
papers demonstrated the special importance of a differential
diagnosis in Africans because this group is characterized by a
high burden of neurological infections which can mimic MS
[49]. The incidence of MS is lower in Hispanics than Caucasians
[48].
7. Conclusions
Changes made over the past few years in the criteria for
diagnosing of MS were aimed at facilitating and speeding up
the diagnostic process. The result of successive modiﬁcations
is a more frequent diagnosis of MS at a very early stage of the
disease [34,51,52].
Currently, the diagnosis, beyond clinical symptoms, is
based primarily on the results of MRI. Non-speciﬁc changes in
the T2 sequence in patients with such symptoms as headache,
dizziness, paraesthesias, pain, or excessive fatigue may be
considered a symptom of MS [53]. This may lead to the over-
interpretation of MRI results, as the lesions in the white matter
are found in 40–95% of patients with other neurological
diseases and in 44% of otherwise healthy individuals (those
over 65 years old) [54]. On the other hand, including MRI in the
criteria has increased the sensitivity of the MS diagnosis (66%
before the era of McDonald criteria, compared with 94% in
2000) [1]. Based on these data, it can be assumed that MRI could
have more value as an exclusion test for other neurological
conditions than as part of the diagnostic criteria for MS [55].
The importance of the differential diagnosis should also be
emphasized. It is estimated that the most frequent pathologies
misdiagnosed as MS are: cerebrovascular disease, migraine
headaches, CNS lymphoma, and ﬁbromyalgia [19]. Many
studies have shown that misdiagnoses are made in up to
20% of patients [15,19,52,53]. Moreover, it is estimated that 75%
of patients diagnosed incorrectly receive disease- modifying
therapies [54]. At best, the only disadvantage is a lack of
treatment efﬁcacy but it might also be harmful to the patient
(e.g. in cases of neuromyelitis optica when the treatment
worsens the patient's clinical condition) [55]. Moreover,
misdiagnosis retards the introduction of proper treatment.
That might be especially important in some potentially
curable diseases such as CNS lymphoma, neuroborreliosis,
and neurosarcoidosis [56]. It is important to establish a single
panel of additional tests to exclude pathologies that mimic MS.
It would be useful to train the radiologists in the differentiation
of demyelinating lesions. We also have to understand that, in
times of greater access to different sources of information,
many patients try to interpret the results of radiological scans
on their own [41].
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 1 3 – 3 2 1320Until a single 'fail-safe' diagnostic test is developed,
neurologists will have to base their diagnosis on the current
or future clinical criteria. It seems that the key to success in
diagnosing MS is a careful analysis. One has to start with a
proper assessment of clinical symptoms, including determin-
ing whether relapse can be diagnosed. The evaluation of the
ﬁrst symptoms is of special importance [56]. The correct
interpretation depends largely on the experience of the
clinician [19].
Conﬂict of interest
None declared.
Acknowledgement and ﬁnancial support
None declared.
Ethics
The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans; Uniform Requirements for manuscripts submit-
ted to Biomedical journals.
r e f e r e n c e s
[1] The history of multiple sclerosis. Rae-Grant AD, Fox RJ,
Bethoux F, editors. Multiple sclerosis and related disorders.
Clinical guide to diagnosis, medical management and
rehabilitation. Cleveland: DemosMedical; 2004. p. 1–11.
[2] Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal
damage in acute multiple sclerosis lesions. Brain 1997;120
(3):393–9.
[3] Hirst C, Ingram G, Swingler R, Swingler R, Compston DA,
Robertson NP. Change in disability in patients with multiple
sclerosis: a 20-year prospective population-based analysis. J
Neurol Neurosurg Psychiatry 2008;79:1137–43.
[4] Gafson A, Giovannoni G, Hawkes Ch. The diagnostic criteria
for multiple sclerosis: from Charcot to McDonald. Mult Scler
Rel Disord 2012;1:9–14.
[5] Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini
SE, Goodin DS, et al. Incidental MRI anomalies suggestive of
multiple sclerosis: the radiologically isolated syndrome.
Neurology 2009;72(9):800–5.
[6] Schumacher GA, Beebe G, Kibler RF, Kurland L, Kurtzke JF,
McDowell F, et al. Problems of experimental trials of
therapy in multiple sclerosis: report by the panel on the
evaluation experimental trials in multiple sclerosis. Ann
NY Acad Sci 1965;122:552–68.
[7] Rose AS, Ellison GW, Myers LW, Tourtellotte WW. Criteria
for the clinical diagnosis of multiple sclerosis. Neurology
1976;26:20–2.
[8] Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA,
Ebers GC, et al. New diagnostic criteria for multiple
sclerosis: guidelines for research protocols. Ann Neurol
1983;13(3):227–31.[9] Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL.
Studies on the natural history of multiple sclerosis: early
prognostic features of the later course of the illness. J Chron
Dis 1977;30:819–30.
[10] Rudick R. Diagnostic criteria in multiple sclerosis: headed in
the right direction but still a ways to go. Ann Neurol 2011;69
(2):234–6.
[11] Josey L, Curely M, Mousavi FJ, Taylor BV, Lucas R, Coulthard
A. Imaging and diagnostic criteria for multiple sclerosis: are
we there yet. J Med Imaging Radiat Oncol 2012;56:588–93.
[12] Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A,
Polman CH, et al. Comparison of MR imaging criteria at ﬁrst
presentation to predict conversion to clinically deﬁnite
multiple sclerosis. Brain 1997;120:2059–69.
[13] Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus
DG, Plant GT, et al. Application of the new McDonald
criteria to patients with clinically isolated syndromes
suggestive of multiple sclerosis. Ann Neurol 2002;52:
47–53.
[14] McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP,
Lublin FD, et al. Recommended diagnostic criteria for
multiple sclerosis: guidelines from the international panel
on the diagnosis of multiple sclerosis. Ann Neurol
2001;50:121–7.
[15] Poser CM. Revisions to the 2001 McDonald diagnostic
criteria. Ann Neurol 2006;59(4):727–8.
[16] Nielsen JM, Uitdehaag BMJ, Polman CH. Long-term follow-
up of suspected though unconﬁrmed MS. Mult Scler
2008;14:985–7.
[17] Tur C, Tintoré M, Rovira A, Nos C, Rio J, Tellez N, et al. Very
early scans for demonstrating dissemination in time in
multiple sclerosis. Mult Scler 2008;14:631–5.
[18] Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP,
Kappos L, et al. Diagnostic criteria for multiple sclerosis:
2005 revisions to the McDonald criteria. Ann Neurol
2005;58:840–6.
[19] Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA,
Filippi M, et al. Diagnostic criteria for multiple sclerosis:
2010 Revisions to the McDonald criteria. Ann Neurol
2011;69:292–302.
[20] Miller DH, Chard DT, Cicarelli O. Clinically isolated
syndromes. Lancet Neurol 2012;11:157–69.
[21] Solomon AJ, Klein E, Bourdette D. Undiagnosing multiple
sclerosis – the challenge of misdiagnosis in MS. Neurology
2012;78:1986–91.
[22] Tintoré M, Rovira A, Rio J, Nos C, Grive E, Sastre-Garriga J,
et al. New diagnostic criteria for multiple sclerosis:
application in ﬁrst demyelinating episode. Neurology
2003;60:27–30.
[23] Lublin FD, Reingold SC. Deﬁning the clinical course of
multiple sclerosis: results of an international survey.
National Multiple Sclerosis Society (USA) Advisory
Committee on Clinical Trials of New Agents in Multiple
Sclerosis. Neurology 1996;46:907–11.
[24] Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS,
Thompson AJ, et al. Deﬁning the clinical course of multiple
sclerosis: the 2013 revisions. Neurology 2014;83:278–86.
[25] Weinshenker BG. Natural history of multiple sclerosis. Ann
Neurol 1994;36(Suppl.):S6.
[26] Eriksson M, Andersen O, Runmarker B. Long-term follow up
of patients with clinically isolated syndromes, relapsing-
remitting and secondary progressive multiple sclerosis.
Mult Scler 2003;9:260–74.
[27] Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural
history of primary progressive multiple sclerosis.
Neurology 2009;73:1996–2002.
[28] Miller DH, Chard DT, Ciccarelli O. Clinically isolated
syndromes. Lancet Neurol 2012 Feb;11(2):157–69.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 1 3 – 3 2 1 321[29] Milo R, Miller A. Revised diagnostic criteria of multiple
sclerosis. Autoimmun Rev 2014;13(4–5):518–24.
[30] Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses
and progression of disability in multiple sclerosis. N Engl J
Med 2000;343(20):1430–8.
[31] Kennedy P. Impact of delayed diagnosis and treatment in
clinically isolated syndrome and multiple sclerosis. J
Neurosci Nurs 2013;45(6 Suppl. 1):S3–13.
[32] Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA,
Freedman MS, et al. Differential diagnosis of suspected
multiple sclerosis: a consensus approach. Mult Scler
2008;14:1157–74.
[33] Okuda DT. Unanticipated demyelinating pathology of the
CNS. Nat Rev Neurol 2009;5:591–7.
[34] Siva A, Saip S, Altinas A, Jacob A, Keegan BM, Kantarci OH.
Multiple sclerosis risk in radiologically uncovered
asymptomatic possible inﬂammatory-demyelinating
disease. Mult Scler 2009;15:918–27.
[35] Swanton JK, Fernando K, Dalton CM, Miszkiel KA,
Thompson AJ, Plant GT, et al. Modiﬁcation of MRI criteria
for multiple sclerosis in patients with clinically isolated
syndromes. J Neurol Neurosurg Psychiatry 2006;77:830–3.
[36] Rudick R, Miller A. Multiple sclerosis or multiple
possibilities. The continuing problem of misdiagnosis.
Neurology 2012;78:1904–6.
[37] Członkowska A. Ewolucja kryteriów rozpoznania
stwardnienia rozsianego - wnioski praktyczne. Med Prakt
Neurologia 2012;04:32–4.
[38] Sellner J, Schirmer L, Hemmer B, Mühlau M. The
radiologically isolated syndrome: take action when the
unexpected is uncovered. J Neurol 2010;10:1602–11.
[39] Tintore M, Rovira A, Martıinez M, Rio J, Diaz-Villoslada P,
Brieva L, et al. Isolated demyelinating syndromes:
comparison of different MR imaging criteria to predict
conversion to clinically deﬁnite multiple sclerosis. Am J
Neuroradiol 2000;21:702–6.
[40] Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M,
et al. Radiologically isolated syndrome: 5-year risk for an
initial clinical event. PLOS ONE 2014;9(90509):1–9.
[41] Xiong YY, Mok V. Age-related white matter changes. J Aging
Res 2011;36:13–9.
[42] Scarpelli M, Salvolini U, Diamanti L, Montironi R,
Chiaromoni L, Maricotti M. MRI and pathological
examination of post-mortem brains: the problem of white
matter high signal areas. Neuroradiology 1994;36:393–8.
[43] Gunning-Dixon F, Brickman A, Cheng J, Alexopoulos GS.
Aging of cerebral white matter: a review of MRI ﬁndings. Int
J Geriatr Psychiatry 2009;24(2):109–17.[44] Patel Y, Bhise V, Krupp L. Pediatric multiple sclerosis. Ann
Indian Acad Neurol 2009;12(4):238–45.
[45] Sadaka Y, Verhey LH, Shroff NM, Branson HM, Arnold DL,
Narayanan S, et al. 2010 McDonald criteria for diagnosing
pediatric multiple sclerosis. Ann Neurol 2012;72(2):211–23.
[46] Peche SS, Ashekhlee A, Kelly J, Lenox J, Mar S. A long-term
follow-up study using IPMSSG criteria in children with CNS
demyelination. Pediatr Neurol 2013;49(5):329–34.
[47] Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale
RC, et al. International Pediatric Multiple Sclerosis Study
Group criteria for pediatric multiple sclerosis and immune-
mediated central nervous system demyelinating disorders:
revisions to the 2007 deﬁnitions. Mult Scler 2013;19
(10):1261–7.
[48] Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N,
Morrow SA, et al. Incidence and prevalence of multiple
sclerosis in Europe: a systematic review. BMC Neurol
2013;13:128.
[49] Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of
multiple sclerosis in multiple racial and ethnic groups.
Neurology 2013 May 7;80(19):1734–9.
[50] Kim SH, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, et al.
Clinical characteristics and outcome of multiple sclerosis in
Korea: does multiple sclerosis in Korea really differ from
that in the Caucasian populations? Mult Scler J 2014;261
(7):1349–55.
[51] Benito-Leon J. Multiple sclerosis: is prevalence rising and is
so why. Neuroepidemiology 2011;37:236–7.
[52] Lebrun C, Bensa C, Debouviere M, De Seza J, Wiertlievski S,
Brochet B, et al. Unexpected multiple sclerosis: follow up of
30 patients with magnetic resonance imaging and clinical
conversion proﬁle. J Neurol Neurosurg Psychiatry
2009;79:195–8.
[53] Nielsen J, Korteweg T, Barkhof F, Uitdehaag BM, Polman CH.
Overdiagnosis of multiple sclerosis and magnetic
resonance imaging criteria. Ann Neurol 2005;58:781–3.
[54] Shirani A, Zhao Y, Karim M. Association between use of
interferon beta and disability in patients with relapsing-
remitting multiple sclerosis. JAMA 2012;308:247–56.
[55] Swanton JK, Rovira A, Tintoré M, Altmann DR, Barkhof F,
Filippi M, et al. MRI criteria for multiple sclerosis in patients
presenting with clinically isolated syndromes: a
multicenter retrospective study. Lancet Neurol 2007;6:
677–86.
[56] Stelmasiak Z, Bartosik-Psujek R, Belniak-Legieć E, Mitosek-
Szewczyk K. Differential diagnosis in multiple sclerosis
description of selected cases. Neurol Neurochir Pol
2000;34:45–53.
